Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P41226

UPID:
UBA7_HUMAN

ALTERNATIVE NAMES:
D8; Ubiquitin-activating enzyme E1 homolog

ALTERNATIVE UPACC:
P41226; Q9BRB2

BACKGROUND:
The Ubiquitin-like modifier-activating enzyme 7, known alternatively as D8 or Ubiquitin-activating enzyme E1 homolog, is crucial for protein ubiquitination, a process vital for protein degradation and signaling. It activates ubiquitin through a two-step reaction involving ATP and links it to E1, creating a ubiquitin-E1 thioester. Additionally, it catalyzes the ISGylation of the influenza A virus NS1 protein, indicating its role in antiviral defense mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ubiquitin-like modifier-activating enzyme 7 offers a pathway to novel therapeutic avenues. Given its central role in ubiquitination and ISGylation, targeting this enzyme could lead to innovative treatments for managing viral infections and disorders associated with protein mismanagement.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.